8-K: Aptose Biosciences Reports Year-End 2024 Results and Highlights Tuspetinib's Potential in AML Treatment

Aptose Biosciences announced its year-end 2024 financial results and provided a corporate update, highlighting the advancement of tuspetinib-based triple drug therapy for acute myeloid leukemia (AML).

Summary

• Aptose Biosciences announced its financial results for the year ended December 31, 2024, and provided a corporate update on March 28, 2025.
• The company is focused on developing tuspetinib (TUS)-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML).
• The TUSCANY Phase 1/2 trial is underway, evaluating TUS in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline therapy for AML.
• The triplet therapy has shown complete remissions (CRs) in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients.
• The trial has escalated to an 80 mg TUS dose level after promising early results and favorable safety at the 40 mg dose level.
• Aptose completed several financings during 2024, totaling approximately $37 million, to support the development of the TUS-based triplet therapy.
• A debt conversion agreement was executed with Hanmi to convert $1.5 million of debt into 409,063 common shares.
• Aptose entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the clinical development of TUS.
• Aptose regained compliance with Nasdaq's minimum bid price requirement.
• The net loss for the year ended December 31, 2024, decreased by $25.8 million to $25.4 million, compared to $51.2 million for the comparable period in 2023.
• Total cash, cash equivalents, and restricted cash equivalents as of December 31, 2024, were $6.7 million.
• The company expects that cash on hand and available capital will fund planned operations until April 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive aspects include promising clinical trial results, strategic collaborations, and reduced net loss. However, concerns remain regarding near-term funding and compliance with Nasdaq's shareholders equity requirement.

Positives

• Tuspetinib shows promise in treating AML, particularly in difficult-to-treat subtypes.
• The TUSCANY trial is progressing with dose escalation based on positive safety and efficacy data.
• Aptose secured significant financing to support its clinical development programs.
• The collaboration with the NCI provides additional opportunities for clinical development of tuspetinib.
• The company regained compliance with Nasdaq's minimum bid price requirement.
• The net loss decreased significantly in 2024 compared to 2023.

Negatives

• The company's cash reserves are projected to only fund operations until April 2025, raising concerns about near-term funding needs.
• Aptose is not in compliance with the $2.5 million shareholders equity requirement and is operating under an exception granted by the Nasdaq Hearing Panel, which provides Aptose additional time to regain compliance, although there is no assurance that the Company will successfully achieve full compliance with the Nasdaq shareholders equity requirement.

Risks

• The company's ability to obtain the capital required for research and operations is a significant risk.
• Early-stage drug development inherently carries risks, including demonstrating efficacy and navigating the regulatory approval process.
• The company's ability to find and enter into agreements with potential partners is uncertain.
• Changing market and economic conditions could impact the company's financial performance.
• Unexpected manufacturing defects could disrupt the development and commercialization of tuspetinib.
• The company's reliance on government programs and the evolving regulatory and political landscape pose risks.

Future Outlook

Aptose expects to report CR/MRD/Safety data from the TUS+VEN+AZA triplet therapy trial, execute a Hanmi/Aptose Collaboration, and report maturing data at the EHA2025 Congress. The company plans to select optimal TUS doses for Phase 2/3 pivotal trials and prepare for the Phase 2 portion of the pivotal program.

Management Comments

• During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML), said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose.
• Tuspetinib brings favorable safety and broad activity across AML genetic subtypes to the TUS+VEN+AZA triplet therapy, which already has achieved complete remissions (CRs) in difficult-to-treat and underserved TP53-mutated/CK AML and FLT3-wildtype AML patients in our ongoing TUSCANY trial.

Industry Context

Aptose is focusing on precision medicine in oncology, specifically hematology, with its lead compound tuspetinib targeting AML. The development of a triplet therapy (TUS+VEN+AZA) aims to improve frontline treatment options for AML patients, addressing unmet needs in specific genetic subtypes. The collaboration with the NCI and participation in the myeloMATCH trials indicate a broader effort to integrate targeted therapies in AML treatment.

Comparison to Industry Standards

• Aptose's tuspetinib is being developed as a kinase inhibitor, similar to other targeted therapies in AML such as FLT3 inhibitors like gilteritinib (Xospata) from Astellas Pharma and midostaurin (Rydapt) from Novartis.
• The combination of tuspetinib with venetoclax and azacitidine mirrors the trend of combining targeted therapies with standard chemotherapy or hypomethylating agents to improve remission rates and overall survival in AML, similar to the venetoclax plus azacitidine regimen which has become a standard of care for older or unfit AML patients.
• The CRADA with the NCI and participation in the myeloMATCH trials is similar to other collaborations between pharmaceutical companies and government research institutions to accelerate the development of novel cancer therapies, such as the NCI-MATCH trial which tests targeted therapies in various cancer types based on their genetic mutations.
• Aptose's focus on mutation-agnostic triplet therapy differentiates TUS from other drugs in development.

Stakeholder Impact

• Shareholders may be impacted by the clinical trial results, financing activities, and compliance with Nasdaq listing requirements.
• Employees are affected by the company's financial stability and research and development progress.
• Patients with AML may benefit from the development of new treatment options.
• Hanmi Pharmaceutical is a key partner in the development of tuspetinib.

Next Steps

• Report CR/MRD/Safety data from TUS+VEN+AZA triplet therapy trial.
• Execute Hanmi/Aptose Collaboration.
• Report maturing data readout from TUS+VEN+AZA triplet therapy trial at EHA2025 Congress.
• Select optimal TUS doses for TUS+VEN+HMA triplet therapy Ph 2/3 pivotal trials.
• Prepare for Ph 2 portion of Ph 2 / Ph 3 pivotal program.

Key Dates

Keywords

tuspetinib, AML, TUSCANY trial, acute myeloid leukemia, oncology, clinical trial, financing, Hanmi, NCI, CRADA, Nasdaq, APTO, Aptose Biosciences